Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Summary

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel

Timeline

Start

2021-11-15

Primary completion

2023-04-01

Completion

2023-04-12

Outcome

Met primary endpoint

paper The incidence of vomiting in both dosing arms of tradipitant was significantly lower than the placebo group across all boat trips PMID 40103934 ↗

paper 170 mg tradipitant = 18.3%, 85 mg tradipitant = 19.5%, placebo = 44.3%, p < 0.0001 for both dose comparisons against placebo). PMID 40103934 ↗

Publications

• Nguyen T, Willett KC, Daly LR, Junker J, Andreescu O, Dima L. Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness. Am J Ther. 2026 Jul-Aug 01;33(4):e324-e328. doi: 10.1097/MJT.0000000000002147. Epub 2026 May 14.
• Polymeropoulos VM, Kiely L, Bushman ML, Sutherland EB, Goldberg AR, Pham AX, Miller CR, Mourad R, Davis TR, Pham NV, Morgan DB, Giles AK, Xiao C, Polymeropoulos CM, Birznieks G, Polymeropoulos MH. Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study. Front Neurol. 2025 Mar 4;16:1550670. doi: 10.3389/fneur.2025.1550670. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tradipitant	Small molecule	85 mg	Oral
Subject	Tradipitant	Small molecule	170 mg	Oral

Indications